EXICURE, INC.
Close on Oct 19, 2026
- Market cap
- $6.57M
- P/E (TTM)
- –
- Dividend yield
- –
About Exicure
Pharmaceutical Preparations, SIC 2834
Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapies based on licensed intellectual property and proprietary technologies. Through its acquired subsidiary, GPCR Therapeutics USA Inc., the company concentrates on therapeutic candidates for oncology, specifically targeting blood cancers such as multiple myeloma. Its primary clinical trial program evaluates the combined administration of the chemokine receptor antagonist GPC-100 with propranolol to mobilize stem cells for patients eligible for bone marrow transplantation. The company has historically explored broader strategic alternatives, acquisitions, and collaborations across the biotechnology sector.
The company's operational activities are concentrated at its single facility located in Redwood City, California, where its corporate headquarters are also situated. As of December 31, 2025, the organization employs eight full-time personnel who oversee general management and administrative functions. Exicure conducts business activities primarily within the United States.
Summary of the business section of Exicure's latest annual report, written by StockData.
Company profile
Company
- Legal name
- EXICURE, INC.
- Founded
- 2011
- Headquarters
- Chicago, IL
- Address
- 2430 N. Halsted St. 60614
- Phone
- (847) 673-1707
- Website
- exicuretx.com
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, New York
Stock & identifiers
- Ticker
- XCUR
- Exchange
- Nasdaq
- IPO date
- May 22, 2018
- Shares outstanding
- 7M, Aug 13, 2026
- Public float
- $16.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-5 reverse, Aug 28, 2024; 1-for-5 reverse, Aug 27, 2024; 1-for-30 reverse, Jun 30, 2022; 1-for-30 reverse, Jun 29, 2022
- SEC CIK
- 1698530
- CUSIP
- 30205M309
- ISIN
- US30205M3097
- LEI
- 549300IMD6I0V06I2Z87
- EIN
- 81-5333008
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Andy Yoo | Chief Restructuring Officer, Director | 73,666 |
| Josh Miller | Chief Accounting Officer | 301 |
| Sangjin Yeo | Director | – |
| Aejin Hwang | Director | – |
| Min Woo Kang | Director | – |
| Ho Jung John | Director | – |
| Chang Keun Choi | Director | – |
| Sang Wook Song | Director | – |
| Seung Ik Baik | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Kang | $170.00K | $170.00K | $87.89K | $53 | – |
| FY2024 Kim | $0 | $0 | $87.89K | $53 | – |
| FY2024 Schroff | $0 | $0 | $87.89K | $53 | – |
| FY2024 Yoo | $27.17K | $27.17K | $87.89K | $53 | – |
| FY2023 Kang | $66.99K | $50.00K | $511.25K | $10 | – |
| FY2023 Kim | $90.94K | $90.94K | $511.25K | $10 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had eight full time employees which were engaged in finance and general management activities after the wind down of our research and development programs.”
Corporate history
Events identified from SEC filings